Article – Pharmaceutical Investing Reimagined | BVE

Navigating the Trough: Turning FDA Setbacks into Leadership Wins

There is significant hype surrounding the potential to break new ground in psychedelic regulations. However, shortly after the CRL was...

Insights

Groundbreaking Study Validates FloraWorks Ultra-Pure Cannabinol-Based Sleep Aid, TruCBN™

Cannabinol (CBN), a non-psychoactive compound derived from cannabis, is gaining attention for its therapeutic potential. In this study, participants reported...

Insights

FDA rejects Lykos MDMA study: Why we support this decision

Today, we’re addressing the recent news that has stirred the psychedelics community — the FDA’s decision to reject Lykos’ application...

Insights

FDA Hearing Votes NO for MDMA Treatment – Why This Is Not the End for Psychedelic Therapy

At Bonaventure Equity, we aim to bring you perspectives from the front lines of investing in controlled substances, delving beyond...

Insights

Schedule III Status Will Promote Cannabis Research and Reduce Stigma — But What About THCs?

The DEA’s rescheduling proposal for cannabis may not yet include THC and other cannabinoids, creating uncertainty. Including THC in the...

Insights

In Context: The Justice Department’s ‘Major’ Step Toward Rescheduling Cannabis

As of now, the process to reschedule cannabis from a Schedule I to a Schedule III drug is well underway...

In Context

Insights from Michael Werner on the DEA’s Move to Reclassify Cannabis

Introduction This landmark decision could mark the most significant federal drug policy shift since the Controlled Substances Act of 1970. Michael...

Insights, Q&A

DEA Agrees to Reschedule Cannabis

In a historic move this week, cannabis rescheduling news went mainstream. This pivotal change will reclassify cannabis from Schedule I...

Breaking, Insights

Explore All Article